1744-22-5

1744-22-5 structure

Name: Riluzole
Chemical Name: 2-Amino-6-(trifluoromethoxy)benzo[d]thiazole
CAS Number: 1744-22-5
Molecular Formula: C₈H₅F₃N₂OS
Molecular Weight: 234.198
Catalog: API Nervous system medication Antiepileptic and anticonvulsant
Create Date: 2018-04-06 08:00:00
Modify Date: 2024-01-02 10:24:50
Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.

Name	2-Amino-6-(trifluoromethoxy)benzo[d]thiazole
Synonyms	MFCD00210213 2-Benzothiazolamine, 6-(trifluoromethoxy)- 2-Amino-6-(trifluoromethoxy)benzothiazole 6-(Trifluoromethoxy)-1,3-benzothiazol-2-amine Riluzole 2-Amino-6-trifluoro methoxy benzothiazole 2-Amino-6-trifluoromethoxybenzothiazole 6-(Trifluoromethoxy)-2-benzothiazolamine Rilutek 6-(Trifluoromethoxy)benzo[d]thiazol-2-amine

Description	Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor Signaling Pathways >> Neuronal Signaling >> GABA Receptor Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease
Target	Sodium channel[1] IC50: 43 μM (GABA receptor)[1]
In Vitro	Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. At 20 μM, Riluzole inhibits peak autaptic IPSCs only slightly but prolongs IPSCs reliably. It is also found that Riluzole causes a strong, concentration-dependent, readily reversible enhancement of responses to 2 μM GABA. At higher concentrations of Riluzole, especially 300 μM, GABA currents exhibit apparent desensitization during prolonged co-exposure to 2 μM GABA and Riluzole. The EC50 of Riluzole potentiation of GABA responses is about 60 μM[1].
In Vivo	In normal naïve rats, systemic injection of Riluzole (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (P<0.05). Systemic application of Riluzole (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (P<0.05 to 0.001). Riluzole administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; P<0.05 to 0.01)[2].
Cell Assay	Two-electrode voltage clamp of Xenopus oocytes expressing exogenous GABAA receptors is performed with a CA-1B high performance oocyte clamp. The extracellular recording solution is ND-96 medium. Riluzole is applied from a common tip via a gravity-driven multibarrel drug-delivery system. Data acquisition and analysis are performed with pCLAMP 6 software[1].
Animal Admin	Adult male Sprague-Dawley rats (180 to 350 g) are housed in a temperature-controlled room and maintained on a 12-h day/night cycle with unrestricted access to food and water. Pain behaviors are measured before and 5 h after induction of a mono-arthritis in the left knee joint. To test the effects of systemic (intraperitoneal, i.p.) application of Riluzole, pain behaviors are measured 1 h postinjection of Riluzole in normal and arthritic animals. To determine effects of Riluzole into the amygdala, pain behaviors are measured 15 min after starting Riluzole application through a stereotaxically implanted microdialysis probe. To investigate site of action in the amygdala of systemically applied Riluzole, potassium channel blockers are administered into the amygdala 45 min after systemic application of Riluzole and pain behaviors are measured 15 min later, i.e., 1 h postinjection of riluzole (i.p.)[2].
References	[1]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. [2]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 28;11:51.

Density	1.6±0.1 g/cm3
Boiling Point	296.3±50.0 °C at 760 mmHg
Melting Point	116-118ºC
Molecular Formula	C₈H₅F₃N₂OS
Molecular Weight	234.198
Flash Point	133.0±30.1 °C
Exact Mass	234.007462
PSA	76.38000
LogP	2.84
Vapour Pressure	0.0±0.6 mmHg at 25°C
Index of Refraction	1.615
Storage condition	Store at RT
Water Solubility	DMSO: ≥25 mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DL2830000

CHEMICAL NAME :: Benzothiazole, 2-amino-6-trifluoromethoxy-

CAS REGISTRY NUMBER :: 1744-22-5

LAST UPDATED :: 199707

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C8-H5-F3-N-O-S

MOLECULAR WEIGHT :: 220.20

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 67 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #50551

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 46 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #50551

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301
Precautionary Statements	P301 + P310
Personal Protective Equipment	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes	T:Toxic;
Risk Phrases	R25
Safety Phrases	S45
RIDADR	UN 2811
WGK Germany	3
RTECS	DL2830000
Packaging Group	II
HS Code	2934999090

461-82-5

1147550-11-5

~78%

1744-22-5

Literature: Anzini, Maurizio; Chelini, Alessia; Mancini, Alessandra; Cappelli, Andrea; Frosini, Maria; Ricci, Lorenzo; Valoti, Massimo; Magistretti, Jacopo; Castelli, Loretta; Giordani, Antonio; Makovec, Francesco; Vomero, Salvatore Journal of Medicinal Chemistry, 2010 , vol. 53, # 2 p. 734 - 744

461-82-5

333-20-0

~87%

1744-22-5

Literature: BRISTOL-MYERS SQUIBB COMPANY; UNIVERSITE DE MONTREAL; LAWRENCE, Michael, R.; MILLER, Michael, M.; SEIFFERT, Dietmar, Alfred; POSY, Shoshana, L.; WONG, Pancras, C.; BANVILLE, Jacques; RUEDIGER, Edward, H.; DEON, Daniel, H.; MARTEL, Alain; TREMBLAY, Francois; GUY, Julia; LAVALLEE, Jean-Francois; GAGNON, Marc Patent: WO2013/163244 A1, 2013 ; Location in patent: Paragraph 00205; 00206 ;

461-82-5